Milestone Pharmaceuticals Files 8-K
Ticker: MIST · Form: 8-K · Filed: May 29, 2024 · CIK: 1408443
Sentiment: neutral
Topics: 8-K, filing, regulatory
TL;DR
Milestone Pharma filed an 8-K on 5/29. No major news yet, just docs.
AI Summary
On May 29, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates Milestone Pharmaceuticals Inc. has submitted required documentation to the SEC, but the specific details of any material events or financial updates are not disclosed in this excerpt.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission without immediate disclosure of significant financial or operational changes.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily concerning 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The date of the earliest event reported is May 29, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Milestone Pharmaceuticals Inc.
Where is Milestone Pharmaceuticals Inc. headquartered?
Milestone Pharmaceuticals Inc. is located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6.
What is the company's telephone number?
The company's telephone number, including area code, is (514) 336-0444.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-29 07:09:13
Filing Documents
- tm2415708d1_8k.htm (8-K) — 25KB
- tm2415708d1_ex99-1.htm (EX-99.1) — 14KB
- tm2415708d1_ex99-1img001.jpg (GRAPHIC) — 31KB
- 0001104659-24-065806.txt ( ) — 261KB
- mist-20240529.xsd (EX-101.SCH) — 3KB
- mist-20240529_lab.xml (EX-101.LAB) — 33KB
- mist-20240529_pre.xml (EX-101.PRE) — 22KB
- tm2415708d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On May 29, 2024, Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") issued a press release announcing that its resubmitted New Drug Application for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia, has been accepted for filing by the U.S. Food and Drug Administration and that the Prescription Drug User Fee Act target date is 10 months from the acceptance date of May 26, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-Kand is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release, dated May 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. Date: May 29, 2024 By: /s/ Amit Hasija Amit Hasija Chief Financial Officer Principal Financial Officer